相关临床试验
539
71 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
66
12.2%
已完成
297
55.1%
No Longer Available
1
0.2%
尚未招募
5
0.9%
招募中
71
13.2%
暂停
7
1.3%
终止
65
12.1%
Unknown
5
0.9%
撤回
22
4.1%
暂无批准数据
- DelveInsight's 2025 pipeline report reveals 45+ companies developing 45+ therapies for cutaneous squamous cell carcinoma, indicating strong industry interest in addressing this aggressive skin cancer. - Recent clinical trials include H. Lee Moffitt Cancer Center testing afatinib for advanced cSCC, Regeneron evaluating neoadjuvant cemiplimab, and Daiichi Sankyo assessing ifinatamab deruxtecan across multiple tumor types. - Leading pipeline candidates include HLX07 (Shanghai Henlius Biotech) in Phase II, Opzelura (Incyte Corporation) in Phase II, and RM-1995 (Rakuten Medical) in Phase I trials. - The therapeutic landscape spans multiple administration routes and molecule types, with companies like Incyte, Novartis, Genentech, and Roche driving innovation in this space.
- The 2025 ASCO Annual Meeting highlighted significant progress in myelofibrosis treatment, featuring novel JAK inhibitors like momelotinib and pacritinib that offer alternatives to standard ruxolitinib therapy. - Momelotinib demonstrated superior anemia management in the MOMENTUM trial with 25% symptom response versus 9% with danazol, particularly benefiting patients with ruxolitinib-induced anemia. - Pacritinib showed consistent efficacy regardless of baseline cytopenias, making it valuable for patients with low platelet counts below 50,000/μL who have limited treatment options. - Pegylated interferons continue to play an important role with 70-80% response rates and superior molecular responses, especially beneficial for younger patients with potential disease-modifying activity.
